Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

Simple Summary FLT3 mutation is commonly present in newly diagnosed patients with
acute myeloid leukemia, and confers high relapse risk. Targeted therapies with FLT3 …

Acute myeloid leukemia (AML) patients often experience poor therapeutic outcomes and
relapse after treatment with single-target drugs, representing the urgent need of new …

Synergetic inhibition of FMS-like tyrosine kinase 3 (FLT3) and histone deacetylase (HDAC)
by small molecule chimera presents a promising therapeutic approach for acute myeloid …

The urgent and unmet medical demand of acute myeloid leukemia (AML) patients has
driven the drug discovery process for expansion of the landscape of AML treatment. Despite …

Simple Summary Acute myeloid leukemia (AML) is a dangerous cancer of the blood. In
recent years, a series of drugs was approved to specifically target misdirected processes in …

Introduction Autophagy is a highly conservative self-degradative process. It aims at
elimination-impaired proteins and cellular organelles. Previous research confirmed the …

Background Acute myeloid leukemia (AML) is characterized by the abnormal proliferation of
myeloid precursor cells and presents significant challenges in treatment due to its …

The most important issues in acute myeloid leukemia are preventing relapse and treating
relapse. Although the remission rate has improved to approximately 80%, the 5-year survival …

Simple Summary The treatment and cure of FLT3-mutated AML (FLT3mut) is still a
challenge despite the availability of mutation-targeted FLT3 inhibitors (FLT3i). This is a …